Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04540107 · ClinicalTrials.gov registry record · Phase 1
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
A Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma, sponsored by Susan Chang.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT04540107: Recruiting Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma, sponsored by Susan Chang.
NCT04540107 is a Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma that is actively recruiting participants, run by Susan Chang. The registered enrollment target is 300 participants, above the 122-participant average among 11 other WHO Grade III Glioma trials with a reported enrollment target (146% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04540107, a Phase 1 study of WHO Grade III Glioma and Recurrent WHO Grade III Glioma, is actively recruiting participants, sponsored by Susan Chang.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
Primary Outcome
Safety evaluation for endpoint will include monitoring for the occurrence of treatment-emergent adverse events (AEs). Reported toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) version 4.0. All available safety data will be used and will be analyzed using descriptive statistics.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Hyperpolarized Carbon C 13 Pyruvate
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
What NCT04540107 shows while recruiting
NCT04540107 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 122-participant average among 11 other WHO Grade III Glioma trials with a reported enrollment target (146% higher).
The record links to 4 conditions, with WHO Grade III Glioma appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT04540107 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04540107 about?
NCT04540107 is a clinical study titled "Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma". This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn mo...
What is the current status of trial NCT04540107?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2017-01-11. Estimated completion is 2027-01-31.
What conditions does trial NCT04540107 study?
This clinical trial studies the following conditions: WHO Grade III Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, Recurrent World Health Organization (WHO) Grade II Glioma.
What interventions are being tested in trial NCT04540107?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG), Magnetic Resonance Spectroscopic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT04540107?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04540107 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for WHO Grade III Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04540107's enrollment target sits among peer trials
300 3rd of 11 higher than 9 of 11 other WHO Grade III Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other WHO Grade III Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI